Clinical collaborations drive cancer immunotherapy


A joint clinical trial agreement between Merck & Co and Pfizer is the latest in what is becoming a rather tangled web of tie-ups between companies with cancer drugs that harness patients’ immune systems. These immuno-oncology drugs stop tumours from disguising themselves from natural defence mechanisms, but work better when more than one of these pathways are blocked simultaneously, or in combination with chemotherapy agents that will attack tumours directly. Hence, companies are touting their products as widely as possible to counterparts with complementary drugs.

This agreement will see Merck & Co’s anti-programmed death-ligand 1 (PD-L1) antibody, pembrolizumab, tested with Pfizer’s lung cancer drug Xalkori (crizotinib) in a Phase 1b trial. Trials of pembrolizumab and a second Pfizer drug at a much earlier developmental stage have also been agreed.

Merck & Co has already signed up several other partners to test combinations of their drugs with pembrolizumab. In February, the company revealed plans involving yet another Pfizer drug – Inlyta (axitinib) for renal cell carcinoma – as well as Amgen’s cancer-killing virus talimogene laherparepvec, and Incyte’s indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.

Incyte itself has struck deals to run trials of INCB24360 with Roche subsidiary Genentech’s anti-PD-L1 antibody MPDL3280A; two antibody treatments from Bristol-Myers Squibb (BMS) (nivolumab and ipilimumab); and MEDI4736, an anti-PD-L1 antibody from AstraZeneca’s biological drugs subsidiary MedImmune.

In turn, several of those drugs are involved in combination trials elsewhere: BMS and Celgene are investigating nivolumab in combination with Abraxane – a version of blockbuster cancer drug Taxol (paclitaxel) bound to the blood protein albumin; and MedImmune has signed up with antibody drugmakers Advaxis in the US and Kyowa Hakko Kirin of South Korea.


Related Content

Pharma vies to unleash immune system power on cancer

12 June 2014 Business

news image

Immuno-oncological drugs look set to earn billions and significantly lengthen patients’ lives

The hunt for innovation

31 January 2014 Premium contentFeature

news image

Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom

Most Read

Antimicrobial resistance will kill 300 million by 2050 without action

16 December 2014 News and Analysis

news image

UK report says resistance will cost global economy $100 trillion

Cutting edge chemistry in 2014

10 December 2014 Research

news image

We take a look back at the year's most interesting chemical science stories

Most Commented

Smart skin for prosthetic limbs senses heat and touch

12 December 2014 Research

news image

Ultra-thin plastic skin can bend and flex without affecting the skin's ability to detect stimuli

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint